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Abstract
Background: The pathophysiological role of SERPINA1 in respiratory health may be more strongly determined by the
regulation of its expression than by common genetic variants. A family based study of predominantly smoking adults
found methylation at two Cytosine-phosphate-Guanine sites (CpGs) in SERPINA1 gene to be associated with chronic
obstructive pulmonary disease risk. The objective of this study was to confirm the association of lung function with
SERPINA1 methylation in general population samples by testing a comprehensive set of CpGs in the SERPINA gene
cluster. We considered lung function level and decline in adult smokers from three European population-based cohorts
and lung function level and growth in tobacco-smoke exposed children from a birth cohort.
Methods: DNA methylation using Illumina Infinium Human Methylation 450 k and EPIC beadchips and lung function were
measured at two time points in 1076 SAPALDIA, ECRHS and NFBC adult cohort participants and 259 ALSPAC children.
Associations of methylation at 119 CpG sites in the SERPINA gene cluster (PP4R4-SERPINA13P) with lung functions and
circulating alpha-1-antitripsin (AAT) were assessed using multivariable cross-sectional and longitudinal regression models.
Results: Methylation at cg08257009 in the SERPINA gene cluster, located 32 kb downstream of SERPINA1, not annotated to a
gene, was associated with FEV1/FVC at the Bonferroni corrected level in adults, but not in children. None of the methylation
signals in the SERPINA1 gene showed associations with lung function after correcting for multiple testing.
Conclusions: The results do not support a role of SERPINA1 gene methylation as determinant of lung function across the life
course in the tobacco smoke exposed general population exposed.
Keywords: Chronic obstructive pulmonary disease; SERPINA1 methylation, DNA methylation, Epigenetics, Population based
study, Smoking, Alpha-1 antitrypsin
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Background
Tobacco smoke represents the most important COPD risk
factor. Yet, not all smokers develop the disease during
their lifetime [1]. The interaction between rare genetically
determined alpha-1 antitrypsin (AAT) deficiencies and
smoking on emphysema risk illustrates the relevance of
genetic susceptibility and gene-environment interactions.
The protease inhibitor AAT, encoded by SERPINA1, pre-
vents the extracellular matrix degradation and destruction
of alveoli by neutrophil. Both, tobacco smoke and AAT
deficiency cause neutrophil recruitment in the lung.
Pro-inflammatory and oxidative processes further dimin-
ish the anti-proteolytic AAT activity [2, 3].
Genome-wide association studies (GWAS) initially
suggested that common SERPINA1 variants might influ-
ence COPD risk and associated lung function pheno-
types. However, reported associations with common
SERPINA1 single nucleotide polymorphisms (SNPs)
were shown to reflect their linkage with more penetrant
rare variants [4, 5]. In a recent GWAS, restricted to
smokers, SERPINA1 variants were not associated with
the level of lung function [6]. In the largest GWAS
meta-analysis to date, a genetic risk score including
95SNPs, independently associated with lung function or
COPD, did not contain SNPs from SERPINA1. Never-
theless, an over-representation of genetic variants related
to elastic-fibre pathway was observed [7].
SERPINA1 gene is complex with eleven splicing iso-
forms differing in the SERPINA1 5’-UTR, tissue expres-
sion and secondary structure. This suggests that the gene’s
pathophysiological role may be more strongly determined
by differences in expression, regulation or posttranscrip-
tional modification than by genetic variation [8]. A recent
family-based study of predominantly smoking adults with-
out severe AAT deficiency investigated SERPINA1 methy-
lation. It was associated with COPD risk, forced
expiratory volume in 1 s (FEV1) and the ratio of FEV1 to
forced vital capacity (FEV1/FVC) [9] at two CpG sites.
Our candidate gene study is the first to investigate the
influence of SERPINA1 methylation on lung function in
a general population. Specifically, we tested the associ-
ation of a comprehensive set of methylation signals in
the SERPINA gene cluster with lung function levels; with
10 to 15-year lung function decline in adult smokers
from three population-based European cohorts; and with
lung function growth in tobacco-smoke exposed chil-
dren from the ALSPAC birth cohort.
Methods
Study design
Cross-sectional and longitudinal analyses used data from
three European adult cohorts and one European birth
cohort with longitudinal data on lung function and
DNA methylation (DNAm).
Ethics approval and consent to participate
All studies were approved by the local ethics committees
and participants or their guardians provided written
consent prior to taking part in the study.
Adult cohorts and participants
Participants came from three population-based studies: Swiss
Study on Air Pollution and Lung and Heart Disease in
Adults (SAPALDIA) [10, 11], European Community Respira-
tory Health Survey (ECRHS) [12] and Northern Finland
Birth Cohort 1966 [13]. Participation across the studies
included structured questionnaires, pre-bronchodilation
spirometry, and blood sampling for DNA extraction and
analysis. SAPALDIA and ECRHS share a harmonized re-
spiratory health protocol. The study sample was restricted to
ever smokers, aged ≥25 years, with data on valid lung
function, relevant covariates, and DNA samples from two
follow-ups subjected to methylome typing in the context of
the Aging Lungs in European Cohorts (ALEC) project. The
final sample size was 1076 (n= 561 SAPALDIA, n= 267
ECRHS, and n= 248 NFBC).
Children and adolescent cohort and participants
The Avon Longitudinal Study of Parents and Children
(ALSPAC) consisted of 68 follow-up assessments between
birth and 18 years [14]. Spirometry was performed at ages
8.5 and 15 years. Participants were restricted to children
and adolescents with DNA methylome and valid lung
function data from two time points, as well as information
on relevant covariates. The study sample included 259
children exposed to tobacco-smoke (mother smoked dur-
ing pregnancy and/or lived with a smoker and/or reported
smoking ≥twice in their lifetime).
Lung function
Pre-bronchodilation spirometry was performed by trained
personnel according to the ATS/ERS recommendations
[15]. FEV1, FVC, and FEV1/FVC were the lung function
parameters considered. In SAPALDIA, parameters were
derived from 2001 and 2010 measurements and corrected
for change in spirometers from SensorMedics to ndd
EasyOne [16] in ERCHS they were derived from 1998 and
2008 measurements and were corrected from several spi-
rometers to ndd EasyOne. In NFBC they were measures
by Vitalograph P-model in 1997 and MasterScreen
Pneumo spirometer in 2012. ALSPAC parameters were
derived from 2000 and 2016 spirometries obtained from
the same brand spirometer [17].
DNA methylation measurement
DNAm of autosomes obtained at two time points of lung
function measurements was the predictor of interest.
DNA was extracted from peripheral whole blood in all co-
horts. In SAPALDIA and ALSPAC, DNAm was measured
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at both time points using the Infinium HumanMethyla-
tion450K BeadChip (Illumina, Inc.), in NFBC using the
Infinium HumanMethylation450K BeadChip at the first
time point and the EPIC BeadChip at the second time
point and in ECRHS, at both time points using the EPIC
BeadChip.
For ECRHS and SAPALDIA, randomized distribution
of samples for bisulphite conversion was applied and for
methylome typing batches, the samples from each time
point from the same person were placed next to each
other on the array. In NFBC1966 DNAm data were re-
corded in two batches following the clinical assessments
of participants aged 31 and 46.
The methylation level (β value) was derived from raw in-
tensities after pre-processing using R package using minfi
[18] followed by beta-mixture quantile normalization
(BMIQ) [19] in SAPALDIA or RnBeads [20] followed by
quantile normalization (QN) in ECRHS. In NFBC, CPA-
COR pipeline [21] was used to pre-process and prepare β
values. In all adult cohorts, normalized beta scores were
regressed on principle components derived from the array
control probes reflecting technical bias. The resulting resid-
uals were used as predictors in the associations with lung
function.
In ALSPAC, analogous standard quality control proce-
dures were applied, in addition, genotype probes on the
HumanMethylation450K were compared between sam-
ples from the same individual and against SNP-chip data
to identify and remove any sample mismatches. Data were
pre-processed in R (version 3.0.1) with the WateRmelon
package according to the subset quantile normalization
approach [22] to reduce the non-biological differences be-
tween probes. Technical batch effect for each methylation
time-point was adjusted for by including ten surrogate
variables into the models.
Methylation signals considered in SERPINA gene cluster
The human serine protease inhibitor (serpin) gene cluster is
located at 14q32. It consists of eleven functionally diverse
serpin genes within a region of approximately 400 kb in
length. Gene sub-clusters consist of four, three, and four
genes each. The best characterized and proximal sub-cluster
with a length of about 107 kb includes SERPINA1 as well as
an antitrypsin-related pseudogene (ATR, SERPINA2;∼13 kb
downstream), the corticosteroid-binding globulin gene
(CBG, SERPINA6;∼68 kb downstream), and the protein Z in-
hibitor gene (ZPI, SERPINA10;∼100 kb downstream).
Because the tissue-specific expression of different genes
in the serpin cluster is regulated by chromosomal elements
and chromatin structure, and in the absence of knowledge
about the relevance of more distal methylation signals on
gene expression, we included in the analysis all 119 CpGs
located 99 kb downstream (PPP4R4) and 376 kb upstream
(GSC) from the SERPINA1 gene. The CpGs were allocated
to 12 genes: PPP4R4, SERPINA10, SERPINA6, SERPINA1,
SERPINA11, SERPINA9, SERPINA12, SERPINA4, SER-
PINA5, SERPINA3, SERPINA13, and GSC (Fig. 1: location
of CpG sites considered; Fig. 2: correlation of methylation
at different CpGs at both time points).
Covariate information
Information on participant’s age, sex, education, height, and
smoking status was derived from questionnaires adminis-
tered during the two time-points. Cell proportions in the
respective blood samples were estimated using the House-
man method [23] implemented in the minfi package [18].
For sensitivity analysis, SAPALDIA provided informa-
tion on concentrations of high-sensitive C-reactive protein
(CRP) and AAT in blood samples collected at the first
time point. CRP and AAT concentrations were measured
by latex-enhanced immunoturbidimetric assays (Roche
Cobas Integra analyzer; Roche Diagnostics). Inter-assay
coefficients of variation were below 5% and lower detec-
tion rate were 0.1 mg/l (CRP) and 0.21 (AAT) [24]. In
addition, SAPALDIA provided genetic information on rare
AAT deficiency variants PiZ and PiS [4].
Statistical analyses
Cohort-specific analyses on lung function and its decline in
adults
Within each adult cohort, four statistical models were
run: a) cross-sectional associations of DNAm with lung
function at T1, b) cross-sectional associations of DNAm
with lung function at T2, c) repeat cross-sectional associa-
tions of DNAm and lung function at both time points,
and d) predictive associations of DNAm at T1 on annual
Fig. 1 Chromosome 14 and SERPINA gene cluster located between PPP4R4 and GSC genes
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lung function decline between T1 and T2, calculated as
(lung function at T2 - lung function at T1 divided by the
time of follow-up in years).
The absolute levels of lung functions (FEV1, FVC, FEV1/
FVC) were regressed on residuals of methylation by fitting
linear regression models and a mixed-model with a
random effect for the subject (repeat cross-sectional
model), respectively. Sample size was kept constant across
all models and analyses. Models were a priori adjusted for
the following covariates associated with lung function
level at P-value < 0.05: study center, age, age2, education,
height, (height-mean(height))2, sex, sex*age, sex*age2,
A
B
Fig. 2 a-b Heatmaps for correlation of methylation at 119 CpGs in SERPINA gene cluster in SAPALDIA. Heatmaps correlations at the first (a; T1) and
second (b; T2) time-points. CpGs located on the SERPINA1 gene are highlighted in black and labeled. Both figures were created with the R software
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sex*height, sex*(height-mean(height))2, and cell compos-
ition (CD8T; CD4T; NK; Bcell; Mono and Eos).
Meta-analysis of adult cohort results
The fixed-effect meta-analysis weighted by the inverse of
variance was completed using METAL on the 119CpG
sites common to all three cohorts [25]. Associations with
P-values< 0.05 were considered as nominally significant.
Since methylation of CpGs in the SERPINA cluster did
not correlate throughout the whole genetic region (Fig. 2),
the total number of CpGs was used as correction for mul-
tiple testing. A Bonferroni corrected P-value< 4.2 × 10− 4
was considered statistically significant. Given the generally
medium-to-high correlation between lung function pa-
rameters, associations of CpGs with different lung func-
tion parameters were not considered independent [7].
Cohort-specific analysis on lung function and its growth in
children and adolescents
Four regression models equivalent to those assessed in
adult cohorts were run to investigate cross-sectional and
predictive associations of methylation at 119 CpGs in the
SERPINA gene cluster with the absolute level and increase
in FEV1, FVC, and FEV1/FVC in children and adolescents.
The models were a priori adjusted for covariates associ-
ated with lung function at P-value< 0.05: study center, age,
mother’s education, height, (height-mean(height))2, sex,
sex*age, sex*height, and estimated cell composition
(CD8T; CD4T; NK; Bcell; Mono; Eos) [23].
Sensitivity analyses
Seven sensitivity analyses were conducted in SAPALDIA:(1)
119 CpGs from T1 were regressed on circulating AAT
measured at T1 [24] by including the same set of covariates
as in cross-sectional models on lung function at T1;(2)
cross-sectional models at T1 were additionally adjusted for
CRP and AAT;(3) for all phenotypes, all four statistical
models were additionally adjusted for the presence of PiS
and PiZ: 0, 1 or 2 alleles;(4) for neutrophils;(5) stratified by
gender;(6) stratified by obesity (BMI 30 < vs. ≥ 30 kg/m2;(7)
and stratified by self-reported asthma (“Have you ever had
asthma?”).
Results
Characteristics of adult cohort participants
Characteristics of the adult participants at the first time
point (T1) and second time point (T2) are presented in
Table 1. SAPALDIA participants were oldest, reported the
highest number of pack-years, had lung function levels
similar to ECHRS, but lower than NFBC, and exhibited the
highest prevalence of COPD based on pre-bronchodilation
spirometry and defined as FEV1/FVC below the lower limit
of normal: in SAPALDIA 15.3% (T1) and 17.1% (T2),
respectively, compared to 10.5% (T1) and 12.7% (T2) in
ECHRS and 2.2% (T1) and 11.4% (T2) in NFBC. The
prevalence of self-reported doctor’s diagnosed asthma was
between 10 and 20%, increasing with aging in all three
cohorts.
Association of methylation at 119 CpGs in the SERPINA1
cluster with lung function in adult ever smokers
SERPINA1
Of the 119 CpGs, 17 were located in the SERPINA1 gene.
DNAm at these 17 sites was not associated with any of the
three lung function parameters at a Bonferroni-corrected
P-value, irrespective of the model considered (Tables 2 and 3;
Additional file 1: Table ES1). However, for FEV1,
meta-analysis revealed three nominally significant associa-
tions at T1 (cg09968361, cg25968219, cg04179148) (Table 2).
The positive association of cg09968361 with levels of FEV1,
nominally significant at T1 (β:1.43, P-value = 0.04) was con-
sistent in direction for T2 and the repeat cross-sectional ana-
lysis (β:0.72, P-value = 0.02). However for change in lung
function, an increase in methylation at this CpG site was as-
sociated with accelerated FEV1 decline (β:-0.10, P-value =
0.011). For FEV1/FVC (Table 3), meta-analysis also revealed
three nominally significant associations at T1 (cg25968219,
cg24621042, cg04179148), which in part overlapped with
those associated with FEV1, also in terms of direction of asso-
ciation. No association of methylation at SERPINA1 CpGs
and FVC was observed (Additional file 1: Table ES1).
SERPINA gene cluster
Results from the meta-analysis on the association of methy-
lation at the 119 CpGs with cross-sectional lung function
and lung function decline for FEV1, FVC and FEV1/FVC
are presented in Additional file 1: Tables ES2-S4. A single
CpG at cg08257009, located 32 kb downstream of SER-
PINA1, withstood Bonferroni-correction for multiple test-
ing. Methylation at this site was positively associated with
FEV1/FVC in the repeat cross-sectional analysis (β:0.11;
P-value = 2.6 × 10− 4) (Additional file 1: Table ES3). The as-
sociations of this signal for the two cross-sectional time
points were comparable (β:0.10; P-value = 0.01 at T1;
β:0.14; P-value = 2.2 × 10− 3 at T2). Consistent with the ob-
servation that higher methylation at this site was associated
with higher level of FEV1/FVC cross-sectionally, it also pre-
dicted attenuated decline of FEV1/FVC (β:0.0089; P-value
= 9.1 × 10− 3).
Association of methylation at 119 CpGs with circulating
alpha-1 antitrypsin in adult ever smokers in SAPALDIA
None of the associations between methylation and cir-
culating AAT in SAPALDIA participants reached
multiple-testing-corrected statistical significance, but
nominal statistical significance was observed at four
CpG sites in the SERPINA1 gene (Tables 2 and 3) and
at two additional sites outside SERPINA1 (Additional
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file 1: Tables ES2-S4), one of which was cg08257009,
the only lung function associated signal withstanding
multiple testing. In all instances, higher methylation
was associated with lower AAT concentrations. These
inverse associations with circulating AAT did not
translate into statistically significant and inverse asso-
ciations with any of the lung function parameters
measured.
Table 1 Population characteristics of adult cohorts
SAPALDIA2
T1, 2001
SAPALDIA3
T2, 2010
ECRHS 2
T1, 1998
ECRHS 3
T2, 2008
NFBC 1966 T1,
1997
NFBC 1966 T2,
2012
N 561 561 267 267 248 248
Female, % 48.3 48.3 52.1 52.1 49.8 48.2
Age (years), mean (SD) 50.4 (10.8) 58.7 (10.7) 44.0 (6.0) 55.0 (6.0) 31.0 (0.3) 46.3 (0.4)
Height (cm), mean (SD) 170.2 (9.2) 169.5 (9.3) 170.0 (9.0) 170.0 (9.0) 172.0 (8.7) 172.0 (8.6)
Weight (kg), mean (SD) 73.9 (14.8) 75.6 (15.6) 74 (15.0) 77 (16.0) 72.1 (12.8) 80.8 (15.3)
Body mass index (kg/m2), mean (SD) 25.4 (4.2) 26.2 (4.6) 25.2 (4.2) 26.8 (4.5) 24.3 (3.6) 27.2 (4.5)
Smoking status, %
Ex-smoker 52.0 63.0 54.7 69.3 46.8 69.2
Current smoker 48.0 37.0 45.3 30.7 53.2 30.8
Pack-years, mean (SD)a 20.4 (20.2) 22.6 (22.1) 17 (17.0) 20 (21.0) 7.7 (5.9) 11.0 (9.6)
Education (%)
SAPALDIA ECRHS & NFBC
Lowb ≤16 yearsc 5.0 4.0 10.9 10.9 0.4 0.4
Intermediate 17–19 years 66.0 67.0 30.5 30.5 61.9 61.9
High 20+ years 29.0 29.0 58.6 58.6 37.7 37.7
FVC (L), mean (SD) 4.4 (1.0) 4.1 (1.0) 4.4 (1.0) 4.0 (1.0) 4.9 (1.0) 4.6 (0.9)
FVC % Predictedd, mean (SD) 106.2 (13.4) 106.0 (13.4) 100.7 (13.0) 99.2 (13.5) 101.8 (10.8) 104.1 (11.2)
FEV1 (L), mean (SD) 3.3 (0.8) 3.0 (0.8) 3.4 (0.8) 3.0 (0.7) 4.1 (0.8) 3.5(0.7)
FEV1% Predicted
d, mean (SD) 99.3 (14.2) 97.9 (16.0) 96.5 (13.7) 93.8 (14.2) 102.1 (11.5) 100.1 (11.8)
FEV1/FVC, mean (SD) 0.8 (0.08) 0.7 (0.08) 0.8 (0.06) 0.8 (0.1) 0.8 (0.05) 0.8 (0.06)
FEV1/FVC % Predicted
d, mean (SD) 93.2 (9.4) 92.0 (9.9) 95.4 (7.7) 94.2 (7.7) 99.9 (6.8) 95.8 (7.0)
CRP (mg/L), mean (SD) 1.92 (2.8) – – – – –
AAT (g/L), mean (SD) 1.27 (0.2) – – – – –
COPD, defined by FEV1/FVC < LLN
e 15.3 17.1 10.5 12.7 2.2 11.4
Doctor-diagnosed asthma, % 15.7 19.1 14.6 17.2 10.5 17.1
Respiratory medication (last 12 months), % 22.5 25.8 12.4 14.3 NA NA
Spirometer brand and model, %
SensorMedics 2200 100.0 – – – – –
EasyOne NDD Medical Technologies – 100.0 – 100.0 – –
SensorMedics 2400 – – 36.0 – – –
Jaeger Pneumotach – – 16.1 – – –
Biomedin Spirometer – – 47.9 – – –
Vitalograph P Model – – – – 100.0 –
MasterScreen Pneumo – – – – – 100.0
Characteristics of ever smokers at first (T1) and second (T2) time points in adult cohorts: SAPALDIA, ECRHS and NFBC 1966
SD standard deviation
aExcluding lifetime non-smokers
bEducation: low corresponding to primary education; intermediate corresponding to secondary, middle, or vocational school; and high corresponding to technical
college or University
cAge at end of studies
dPercentage of the predicted value estimated using GLI equations
eLLN, lower limit of normal estimated using GLI2012 reference equations
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Association of methylation at 119 CpGs with lung
function in tobacco-smoke exposed children and
adolescents
Characteristics of ALSPAC children and adolescents
from the first (T1) and second (T2) time points are pre-
sented in Table 4. Height and weight increased during
follow-up from a mean of 133 to 170 cm and from 31 to
63 kg, respectively. Twenty-two and 29% of children and
adolescents had asthma and at the second time point,
the majority (86%) of adolescents reported intake of
asthma medication in the last 12 months. While FEV1
and FVC increased during follow-up, on average, FEV1/
FVC remained stable.
SERPINA1
Focusing on the methylation sites in SERPINA1 (Additional
file 1: Tables ES5-S7), again none of the signals reached
Bonferroni-corrected significance in association with any
lung function parameter or model. There were several
nominally statistically significant associations, particularly
for lung function growth (FEV1: cg26938334; FVC:
cg26938334, cg13826459, cg 24,621,042; FEV1/FVC:
cg10070185). Methylation at cg26938334 was inversely
associated with growth in FEV1 and FVC, and methylation
at cg24621042 and cg10070185 was inversely associated
with growth in FVC and in FEV1/FVC, respectively. The
associations of cg24621042 with FEV1/FVC change were
inconsistent with those observed for FEV1/FVC decline in
adults.
SERPINA gene cluster
Results from meta-analysis on the association of methyla-
tion at all 119 CpGs with cross-sectional lung function and
lung function growth of FEV1, FVC and FEV1/FVC are pre-
sented in Additional file 1: Tables ES5-S7. No methylation
signals remained statistically significant after Bonferroni
correction. Methylation at cg08257009, 32 kb downstream
of SERPINA1 gene, which showed statistically significant
positive association with FEV1/FVC cross-sectionally in the
adult cohort, was not associated with FEV1 or FEV1/FVC
in children. However, there was evidence for an inverse, ra-
ther than a positive association with FVC at T1 (β:-0.91,
P-value = 4.4 × 10− 3, Additional file 1: Table ES6). Overall,
none of the SERPINA1 CpGs showed consistent associa-
tions across cross-sectional and longitudinal models.
Table 4 Characteristics of tobacco-smoke exposed children and adolescentsa, ALSPAC
Children Cross-Sectional T1 (2000) Adolescents Cross-Sectional T2 (2007)
N 259 259
Females (%) 53.7 53.7
Age (years), mean (SDb) 8.6 (0.2) 15.4 (0.3)
Height (cm), mean (SD) 133.3 (6.0) 170.2 (8.0)
Weight (kg), mean (SD) 31.3 (6.3) 62.8 (11.0)
BMI 17.4 (2.5) 21.7 (3.3)
Maternal Education (%)
Ordinary Level or Lower 56.4 56.4
Advanced Level 27.8 27.8
University 15.8 15.8
Asthmatics (%) 21.6 28.9
Smoking Exposure (%)
In-utero smoking (smoking mother) 25.1 25.1
Second-hand exposure at home 56.0 56.0
Self-exposure (smoked > 2 times in a life-time) 52.1 52.1
COPD [FEV1/FVC < LLN
c] (%) 5.0 4.6
Asthma medications in the last 12 months (%) 14.0 14.0
FVC(L), mean (SD) 2.0 (0.3) 3.9 (0.9)
FEV1(L), mean (SD) 1.7 (0.3) 3.4 (0.7)
FEV1/FVC(L), mean (SD) 0.9 (0.06) 0.9 (0.07)
aChildren and adolescents exposed to tobacco-smoke defined as: mother smoked during pregnancy and/or lived with a smoker and/or reported smoking ≥ twice
in their lifetime
bSD, standard deviation
cLLN, lower limit of normal estimated using GLI2012 reference equations
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Replication of previously reported COPD signals
Relative hypomethylation of cg02181506 and cg24621042
were previously associated with COPD [9]. Table 5 sum-
marizes the association of both signals with circulating
AAT in SAPALDIA and with lung function and its change
in adults as well as children. Contrary to expectation, rela-
tive hypermethylation, not hypomethylation at these two
sites was associated with lower circulating AAT. For
cg02181506, irrespective of age, no association of methyla-
tion with either FEV1/FVC or FEV1 was observed. For
cg24621042, in adults, hypermethylation was positively as-
sociated with FEV1/FVC at T1 only, but not in the repeat
cross-sectional analysis, and the inverse association of
methylation at cg24621042 and FVC change was only ob-
served in children. No lung function associations reached
statistical significance at the nominal P-value< 0.05.
Sensitivity analyses in the SAPALDIA cohort
In the absence of consistent CpG and lung function associ-
ations, we restricted sensitivity analyses to the FEV1/FVC
association between the CpG withstanding multiple testing
(cg08257009) and the two CpGs (cg02181506 and
cg24621042) previously associated with COPD [9] (Table 6,
Additional file 1: Tables ES8-S9). Sensitivity analyses did
not reveal a more consistent pattern of associations be-
tween methylation at these three sites and lung function.
Discussion
This is the first study to investigate the association of DNAm
in the SERPINA gene cluster with lung function and its
longitudinal change in ever-smoking adults from three
European population-based adult cohort studies and in
tobacco-smoke exposed children and adolescents from
England. We observed methylation at cg08257009 not anno-
tated to a gene in the SERPINA gene cluster, located 32 kb
downstream of the SERPINA1 gene to be significantly associ-
ated with FEV1/FVC at the Bonferroni-corrected level. No
methylation signals in the SERPINA1 gene showed
associations with lung function level or change over time
after correcting for multiple testing.
Few studies have reported associations between
DNAm and lung function or COPD. Our results ob-
tained in general population samples contradict the pre-
vious finding of hypomethylation at two CpG sites in
SERPINA1 and COPD risk in two family-based studies.
The first of these studies was restricted to smokers and
the second consisted of participants with and without a
history of smoking [9]. The functional relevance of the
two CpG sites remains unclear, given that the associa-
tions of hypomethylation with COPD risk and circulat-
ing AAT are inconsistent in direction. Consistent with
the inverse association observed with AAT in the blood,
hypomethylation of the AAT gene has been associated
with increased gene expression in rat models [26].
Our results are consistent with the results from a study
comparing gene methylation in lung tissue of former smoker
COPD patients and controls with normal lung function [27,
28]. Methylation in SERPINA1 was not associated with
COPD risk. Similarly no cross-sectional association with
post-bronchodilation lung function was observed for SER-
PINA1 gene methylation measured in blood samples from a
small rural Korean COPD case-control study [29]. Further-
more, in a study of middle-aged monozygotic twins, DNAm
in SERPINA1 was not associated with intra-pair differences
in lung function decline [30].
Smoking exerts strong adverse effects on lung function
and increases COPD risk. In a small proportion of smokers,
it interacts with genetically determined rare AAT deficiency
to cause COPD. The adverse respiratory effects on the lung
tissue may therefore be mediated by altering DNAm in
SERPINA1. Yet, the largest epigenome-wide association
study for smoking did not identify a relevant association be-
tween epigenetic signatures in SERPINA1 and smoking
[31]. Interestingly, the cg08257009 which reached Bonfer-
roni corrected significance in the repeat cross-sectional
analysis was previously reported as a smoking-related CpG
in buccal cells in epithelial cancer [32]. In addition,
cg08257009 and cg02181506 were reported to be smoking
related signals in blood-derived DNA samples from partici-
pants in 16 cohorts, with cg02181506 showing weaker asso-
ciations [31].
Table 5 Association of previously reported COPD associated
cg02181506 and cg2462102
Circulating AATa cg02181506 cg24621042
Coef. Pvalue Coef. Pvalue
− 0.78 0.08 − 0.68 0.04
Adults (SAPALDIA, NFBC66, ECRHS)
FEV1, repeat cross-sectional 0.28 0.47 −0.15 0.60
FEV1, change 0.02 0.71 −0.01 0.87
Children and Adolescents (ALSPAC)
FEV1, repeat cross-sectional 1.42 0.35 0.31 0.29
FEV1, change −0.54 0.26 − 0.17 0.06
Adults (SAPALDIA, NFBC66, ECRHS)
FEV1/FVC, repeat cross-sectional −0.03 0.58 0.07 0.09
FEV1/FVC, change 0.00 0.80 −0.01 0.09
Children and Adolescents (ALSPAC)
FEV1/FVC, repeat cross-sectional 0.01 0.98 0.08 0.07
FEV1/FVC, change −0.12 0.06 0.00 0.71
Direction of effect for SAPALDIA, ECRHS and NFBC: a positive sign indicates
that an increase in methylation is associated with higher level of lung function
(cross-sectional models) and with an attenuation of lung function decline in
the prediction models (change in lung function). In ALSPAC children, a
positive sign indicates that an increase in methylation is associated with
higher level of lung function (cross-sectional models) and with lung function
growth in the prediction models (change in lung function)
Association of Previously Reported COPD Associated cg02181506 and
cg2462102 with Circulating AAT and Lung Function in Adults, Children
and Adolescents
a SAPALDIA cohort, first time point
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The use of blood instead of lung tissue to assess lung
disease related methylation may be considered a limitation
of the study. However as previously discussed, COPD is a
systemic disease related to low grade inflammation, which
supports studying the peripheral blood methylome [9].
Teschendorff and others demonstrated the correlation be-
tween smoking related DNAm in blood and lung tissue as
well as between normal and malignant lung tissue. Their
results also pointed to the prognostic value of these sig-
nals in lung cancer patients [32–34].
Additional limitations of the study include the lack of
cross–omics data to investigate the biological network
related to AAT more comprehensively. This is import-
ant, given the fact that the most recent lung function
GWAS suggests an important role of elastic-fibre path-
ways [7]. Furthermore, misclassification of smoking ex-
posure could have biased the observed associations,
most likely towards the null.
The advantages of the current study are several fold.
First, the studies providing data for this investigation are
well established respiratory population-based cohorts.
They are known for high quality testing of lung function
and large sample sizes. They share similarities in study
protocols. Methylome analyses followed stringent quality
control. Second, the study is based on longitudinal lung
function data and prospectively and repeatedly measured
DNAm. Repeated assessment of lung function and pre-
dictors may have helped improve the statistical power of
the cross-sectional analysis. Prospective assessment of
DNAm with change in lung function decreases the prob-
lem of reverse causation. Third, the integration of lung
function from both adults and children offered the op-
portunity to study SERPINA1 methylation and lung
function over the life course and investigate whether
relevant time windows for genome-environment interac-
tions may exist.
Table 6 Sensitivity Analyses of Association between FEV1/FVC and Methylation at cg02181506, cg2462102, and cg08257009,
SAPALDIA Cohort
cg02181506 cg24621042 cg08257009
Coef. Pvalue Coef. Pvalue Coef. Pvalue
FEV1/FVC repeat cross-sectional
Main modela −0.01 0.93 0.05 0.54 0.07 0.12
Adjustment for PiS and PiZ genotype −0.01 0.94 0.05 0.54 0.07 0.12
Adjustment for neutrophils at T1 and T2 −0.00 0.97 0.05 0.52 0.07 0.11
Men 0.03 0.86 0.07 0.47 0.10 0.11
Women −0.07 0.65 0.06 0.62 0.05 0.49
Not obese (BMI < 30 kg/m2) −0.06 0.58 0.04 0.60 0.12 0.01
Obese (BMI ≥ 30 kg/m2) 0.19 0.25 0.06 0.68 −0.12 0.14
No self-report of ever asthma at T1 and T2 −0.03 0.78 0.07 0.35 0.08 0.09
Asthma ever self-report at T1 or T2 0.14 0.44 −0.05 0.72 −0.01 0.88
FEV1/FVC change
b
Main modelc −0.01 0.60 −0.01 0.49 0.02 0.005
Adjustment for circulating hs-crp and AATd −0.008 0.56 −0.007 0.01 0.02 0.006
Adjustment for PiS and PiZ genotype −0.01 0.57 −0.01 0.48 0.02 0.005
Adjustment for neutrophils at T1 and T2 −0.01 0.44 −0.01 0.36 0.02 0.01
Men 0.01 0.77 −0.00 0.74 0.02 0.01
Women −0.03 0.14 −0.01 0.56 0.02 0.08
Not obese (BMI < 30 kg/m2) at T1 −0.00 0.84 −0.00 0.87 0.02 0.01
Obese (BMI ≥ 30 kg/m2) at T1 −0.04 0.13 −0.04 0.07 0.02 0.17
No self-report of ever asthma at T1 and T2 −0.01 0.57 −0.01 0.40 0.01 0.04
Asthma ever self-report at T1 or T2 −0.03 0.28 0.01 0.65 0.03 0.04
aAdjusted for: study center, age, age2, education, height, height2, sex, sex*age, (sex*age)2, sex*height, (sex*height)2, Bcell, CD4T, CD8T, Eos, Mono, NK and ran with
a random intercept on the subject
bDirection of effect. A positive sign indicates that an increase in methylation is associated with higher level of lung function (cross-sectional models) and with an
attenuation of lung function decline in the prediction models (change in lung function)
cAdjusted for covariates at T1: study center, age, age2, education, height, height2, sex, sex*age, (sex*age)2, sex*height, (sex*height)2, Bcell, CD4T, CD8T, Eos, Mono,
NK. Change in lung function was computed as the difference between T2 and T1 divided by time of follow-up: (T2-T1)/follow-up
dCirculating hs-crp and AAT available from T1 only
Statistically significant results are highlighted in bold
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Conclusion
In conclusion, this first comprehensive study on DNAm
in the SERPINA gene cluster provides weak evidence of an
association with lung functions and its change across the
life course. Larger studies based on post-bronchodilation
lung function need to be followed by investigating associa-
tions of SERPINA1 and elastin-related pathways and net-
works through cross–omics approaches.
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